All MRNA Content

Moderna, Inc (MRNA) European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19

Moderna, Inc (NASDAQ: MRNA) FY 2026 Other Release

February 27, 20261 min read

Moderna, Inc (MRNA) Sec Form 10K

Moderna, Inc (NASDAQ: MRNA) Sec Form 10K

February 22, 20261 min read

Moderna, Inc (MRNA) Barclays 28th Annual Global Healthcare Conference

Moderna, Inc (NASDAQ: MRNA) FY 2026 Corporate Conference

February 19, 20261 min read

Moderna, Inc (MRNA) TD Cowen 46th Annual Healthcare Conference

Moderna, Inc (NASDAQ: MRNA) FY 2026 Corporate Conference

February 19, 20261 min read

Moderna, Inc (MRNA) Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission

Moderna, Inc (NASDAQ: MRNA) FY 2026 Other Release

February 18, 20261 min read

Moderna, Inc (MRNA) Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE

Moderna, Inc (NASDAQ: MRNA) FY 2026 Other Release

February 17, 20261 min read

Earnings

Moderna Q4 2025 net loss narrows; revenue drops 30%

  Moderna, Inc. (NASDAQ: MRNA) has reported a narrower net loss for the fourth quarter of fiscal 2025, when the...

February 16, 20261 min read

Moderna, Inc (MRNA) Sec Form 8K

Moderna, Inc (NASDAQ: MRNA) Sec Form 8K

February 14, 20261 min read

Analysis

Moderna Reports 4Q Revenue Of $678 Million, Projects 2026 Growth

Moderna Inc. (NASDAQ: MRNA) reported fourth-quarter 2025 revenue of $678 million, a 30% decrease from $966 million in the same...

February 13, 20263 min read

Moderna, Inc (MRNA) Q4 2025 Earnings Results

Moderna, Inc (NASDAQ: MRNA) Q4 2025 Earnings Release

February 13, 20261 min read